ATE331719T1 - Verwendung von kristallformen von 2- methylthienobenzodiazepinen - Google Patents

Verwendung von kristallformen von 2- methylthienobenzodiazepinen

Info

Publication number
ATE331719T1
ATE331719T1 AT03077455T AT03077455T ATE331719T1 AT E331719 T1 ATE331719 T1 AT E331719T1 AT 03077455 T AT03077455 T AT 03077455T AT 03077455 T AT03077455 T AT 03077455T AT E331719 T1 ATE331719 T1 AT E331719T1
Authority
AT
Austria
Prior art keywords
methylthienobezodiazepines
crystal forms
crystal
forms
Prior art date
Application number
AT03077455T
Other languages
English (en)
Inventor
Charles Arthur Bunnell
Barry Arnold Hendriksen
Samuel Dean Larsen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE331719(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE331719T1 publication Critical patent/ATE331719T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
AT03077455T 1995-03-24 1996-03-22 Verwendung von kristallformen von 2- methylthienobenzodiazepinen ATE331719T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40956695A 1995-03-24 1995-03-24

Publications (1)

Publication Number Publication Date
ATE331719T1 true ATE331719T1 (de) 2006-07-15

Family

ID=23621056

Family Applications (4)

Application Number Title Priority Date Filing Date
AT00203573T ATE251627T1 (de) 1995-03-24 1996-03-22 Verfahren und kristallformen von 2- methylthienobenzodiazepinen
AT96302000T ATE204280T1 (de) 1995-03-24 1996-03-22 Kristallformen eines thieno(2,3-b)(1, 5)benzodiazepinderivates und verfahren zu deren herstellung
AT0902196A AT406771B (de) 1995-03-24 1996-03-22 Neue kristalline form von 2-methyl-4-(4-methyl- 1-piperazinyl)-1oh-thieno (2,3-b) (1,5)-benzodiazepin, verfahren zu deren herstellung, pharmazeutische mittel und deren verwendung
AT03077455T ATE331719T1 (de) 1995-03-24 1996-03-22 Verwendung von kristallformen von 2- methylthienobenzodiazepinen

Family Applications Before (3)

Application Number Title Priority Date Filing Date
AT00203573T ATE251627T1 (de) 1995-03-24 1996-03-22 Verfahren und kristallformen von 2- methylthienobenzodiazepinen
AT96302000T ATE204280T1 (de) 1995-03-24 1996-03-22 Kristallformen eines thieno(2,3-b)(1, 5)benzodiazepinderivates und verfahren zu deren herstellung
AT0902196A AT406771B (de) 1995-03-24 1996-03-22 Neue kristalline form von 2-methyl-4-(4-methyl- 1-piperazinyl)-1oh-thieno (2,3-b) (1,5)-benzodiazepin, verfahren zu deren herstellung, pharmazeutische mittel und deren verwendung

Country Status (49)

Country Link
US (1) US5736541A (de)
EP (3) EP0733635B1 (de)
JP (1) JPH11502535A (de)
KR (1) KR100399688B1 (de)
CN (1) CN1065536C (de)
AP (1) AP828A (de)
AR (2) AR010448A1 (de)
AT (4) ATE251627T1 (de)
AU (1) AU706471B2 (de)
BG (1) BG62619B1 (de)
BR (1) BR9607790A (de)
CA (1) CA2214005C (de)
CH (1) CH690579A5 (de)
CO (1) CO4650278A1 (de)
CZ (1) CZ292688B6 (de)
DE (4) DE69636313T2 (de)
DK (4) DK1095941T3 (de)
EA (1) EA000149B1 (de)
EE (1) EE03489B1 (de)
EG (1) EG23659A (de)
ES (3) ES2159346T3 (de)
FI (1) FI973750A0 (de)
GB (1) GB2313835B (de)
HK (1) HK1013988A1 (de)
HU (1) HU224989B1 (de)
IL (1) IL117610A (de)
IS (1) IS1896B (de)
LT (1) LT4349B (de)
LU (1) LU90096B1 (de)
LV (1) LV12018B (de)
MY (1) MY114701A (de)
NO (1) NO314663B1 (de)
NZ (1) NZ306110A (de)
OA (1) OA10510A (de)
PA (1) PA8353701A1 (de)
PE (1) PE44897A1 (de)
PL (1) PL183723B1 (de)
PT (3) PT1095941E (de)
RO (1) RO118872B1 (de)
SE (1) SE9703205D0 (de)
SI (4) SI9620040B (de)
SK (1) SK284143B6 (de)
SV (1) SV1996000031A (de)
TR (1) TR199701017T1 (de)
TW (2) TW513432B (de)
UA (1) UA44765C2 (de)
WO (1) WO1996030375A1 (de)
YU (1) YU49478B (de)
ZA (2) ZA962344B (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
AU7013196A (en) * 1995-09-29 1997-04-17 Eli Lilly And Company Method for treating a tic disorder
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
CN1494907A (zh) * 1996-03-25 2004-05-12 治疗疼痛的药物组合物
CA2248873A1 (en) * 1996-03-25 1997-10-02 Daniel Edward Womer Method for treating pain
CA2250155A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Anesthetic method
KR20000004966A (ko) * 1996-03-25 2000-01-25 피터 지. 스트링거 편두통 치료 방법
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
NZ334346A (en) * 1996-09-23 2000-05-26 Lilly Co Eli Olanzapine dihydrate D comprising 2-methyl-4-(4-methyl-1-piperazinyl)-1OH-thieno[2,3-b][1,5]benzodiazepine and a formulation for use in treating central nervous system disorders
AU6955998A (en) * 1997-04-15 1998-11-11 Eli Lilly And Company Method for providing neuro-protective effects
DK1155696T3 (da) * 1997-04-15 2004-07-12 Lilly Co Eli Anvendelse af olanzapin til fremstillingen af et medikament til neurobeskyttelse
US20030022889A1 (en) * 1997-04-15 2003-01-30 Bymaster Franklin P. Method for providing neuro-protective effects
ZA982917B (en) * 1997-04-15 1999-10-06 Lilly Co Eli Method for treating cerebral focal stroke.
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
CN1146422C (zh) * 1998-09-30 2004-04-21 伊莱利利公司 2-甲基-噻吩并-苯并二氮杂�制剂
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
ATE293113T1 (de) * 1999-12-28 2005-04-15 Cipla Ltd Neue polymorphe formen von olanzapin
CA2420987A1 (en) * 2000-08-31 2002-03-07 Dr. Reddy's Laboratories Ltd. Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
AU2001282913A1 (en) * 2000-09-08 2002-03-22 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
US6740753B2 (en) * 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
CA2464306A1 (en) * 2001-10-29 2003-05-08 Dr. Reddy's Laboratories Ltd. Olanzapine dihydrate-ii a process for its preparation and use thereof
JP4530664B2 (ja) * 2001-12-24 2010-08-25 サン・ファーマシューティカル・インダストリーズ・リミテッド ２−メチル−４−（４−メチル−１−ピペラジニル）−１０Ｈ−チエノ［２，３−ｂ］［１，５］ベンゾジアゼピンの結晶形Ｉ、この結晶形Ｉの製造方法、及び医薬組成物
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2003074474A2 (en) * 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
WO2004089313A2 (en) * 2003-04-01 2004-10-21 Transform Pharmaceuticals, Inc. Novel olanzapine forms and related methods of treatment
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
PL196814B1 (pl) * 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
AU2003237305A1 (en) 2002-05-31 2003-12-19 Geneva Pharmaceuticals, Inc. Process of preparation of olanzapine form i
CN100360117C (zh) * 2002-06-21 2008-01-09 转化医药公司 具有提高的溶出度的药物组合物
SI21270A (sl) 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
AU2003300324A1 (en) 2002-12-24 2004-07-22 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
PL1507531T3 (pl) * 2003-03-12 2007-06-29 Teva Pharma Trwałe kompozycje farmaceutyczne desloratadyny
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
CA2546200A1 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
ATE397611T1 (de) * 2003-12-22 2008-06-15 Teva Pharma Verfahren zur herstellung von olanzapin
ATE504588T1 (de) 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
ES2303462B1 (es) * 2004-09-06 2009-06-05 Shasun Chemicals And Drugs Limited Nuevo procedimiento para la preparacion de una forma polimorfica i de olanzapina farmaceuticamente pura.
ES2526092T3 (es) * 2004-11-16 2015-01-05 Alkermes Pharma Ireland Limited Formulaciones de olanzapina en nanopartículas inyectables
PL1838716T3 (pl) 2005-01-05 2011-09-30 Lilly Co Eli Dihydrat embonianu olanzapiny
CZ297214B6 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
KR20070113277A (ko) * 2005-03-21 2007-11-28 닥터 레디스 레보러터리즈 리미티드 올란자핀의 결정 형태 ｉ의 제조방법
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
WO2007020080A1 (en) * 2005-08-17 2007-02-22 Synthon B.V. A process for making olanzapine form i
GB0522474D0 (en) 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
HUP0501046A2 (en) * 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US8367580B2 (en) 2006-03-07 2013-02-05 Ncr Corporation Dual-sided thermal security features
US8721202B2 (en) 2005-12-08 2014-05-13 Ncr Corporation Two-sided thermal print switch
US8222184B2 (en) 2006-03-07 2012-07-17 Ncr Corporation UV and thermal guard
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2591644A1 (en) * 2007-06-14 2008-12-14 Apotex Pharmachem Inc. Novel processes to form-i of olanzapine
US9056488B2 (en) 2007-07-12 2015-06-16 Ncr Corporation Two-side thermal printer
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (de) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Olanzapinreinigungsverfahren
CA2807965C (en) 2010-08-23 2016-03-15 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
CN102093386B (zh) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 一种制备奥兰扎平晶型ⅱ的方法
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
PT2888590T (pt) 2012-08-21 2020-09-11 Janssen Pharmaceutica Nv Anticorpos para olanzapina e utilização destes
WO2014031656A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to olanzapine haptens and use thereof
ES2926662T3 (es) 2012-08-21 2022-10-27 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de risperidona y uso de los mismos
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103848847B (zh) * 2012-12-04 2018-02-06 广东东阳光药业有限公司 一种改进制备奥氮平及其晶型ii的方法
JP6008734B2 (ja) * 2012-12-20 2016-10-19 株式会社トクヤマ オランザピンｉｉ型結晶の製造方法
CN103145731B (zh) * 2013-02-26 2014-02-19 江苏豪森药业股份有限公司 奥氮平晶型及其制备方法和用途
WO2023139531A1 (en) 2022-01-20 2023-07-27 Teva Pharmaceuticals International Gmbh Olanzapine, compositions thereof and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) 1977-07-20 1981-03-10 George K. E. Gregory Packages
US4237279A (en) * 1979-07-27 1980-12-02 Eli Lilly And Company Crystalline 3-hydroxycephalosporin solvates
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
NO305125B1 (no) * 1992-05-29 1999-04-06 Lilly Industries Ltd Farmas°ytiske forbindelser
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine

Also Published As

Publication number Publication date
DE69630324D1 (de) 2003-11-13
DK1445259T3 (da) 2006-10-16
GB2313835A (en) 1997-12-10
TW513432B (en) 2002-12-11
PE44897A1 (es) 1997-10-22
NO974365L (no) 1997-09-22
ES2266719T3 (es) 2007-03-01
MY114701A (en) 2002-12-31
DE69636313T2 (de) 2007-05-31
LT4349B (lt) 1998-05-25
ZA962344B (en) 1997-09-22
YU17796A (sh) 1999-03-04
ATE251627T1 (de) 2003-10-15
LV12018B (en) 1998-09-20
DK0733635T3 (da) 2001-10-08
CN1065536C (zh) 2001-05-09
LT97148A (en) 1998-01-26
TR199701017T1 (xx) 1998-01-21
CO4650278A1 (es) 1998-09-03
TW442488B (en) 2001-06-23
WO1996030375A1 (en) 1996-10-03
EP1445259A1 (de) 2004-08-11
HUP9802824A2 (hu) 1999-06-28
SI9620040B (sl) 2002-02-28
DE69630324T2 (de) 2004-07-29
SI9620040A (sl) 1998-06-30
IS4564A (is) 1997-09-22
FI973750A (fi) 1997-09-22
ATE204280T1 (de) 2001-09-15
DK108997A (da) 1997-11-12
EE03489B1 (et) 2001-08-15
CA2214005C (en) 2001-07-03
EP1095941A1 (de) 2001-05-02
SV1996000031A (es) 1998-03-27
DE69614426T2 (de) 2002-05-23
AR002719A1 (es) 1998-04-29
SI1095941T1 (en) 2003-12-31
JPH11502535A (ja) 1999-03-02
HK1013988A1 (en) 1999-09-17
DE69614426D1 (de) 2001-09-20
MX9707183A (es) 1997-11-29
IL117610A (en) 2001-08-26
EA000149B1 (ru) 1998-10-29
SK284143B6 (sk) 2004-10-05
PL183723B1 (pl) 2002-07-31
BG101900A (en) 1999-03-31
LV12018A (lv) 1998-04-20
HU224989B1 (en) 2006-05-29
LU90096B1 (fr) 1997-07-22
CZ292688B6 (cs) 2003-11-12
CH690579A5 (de) 2000-10-31
HUP9802824A3 (en) 2000-01-28
EA199700262A1 (ru) 1998-02-26
ES2208220T3 (es) 2004-06-16
PT733635E (pt) 2001-12-28
PT1095941E (pt) 2004-02-27
SI0733635T1 (en) 2002-06-30
DK1095941T3 (da) 2004-02-16
PA8353701A1 (es) 1998-09-18
PT1445259E (pt) 2006-10-31
SK121897A3 (en) 1998-03-04
AU5427996A (en) 1996-10-16
RO118872B1 (ro) 2003-12-30
SE9703205L (sv) 1997-09-05
NO314663B1 (no) 2003-04-28
IL117610A0 (en) 1996-07-23
FI973750A0 (fi) 1997-09-22
KR19980703188A (ko) 1998-10-15
EP1095941B1 (de) 2003-10-08
DE69636313D1 (de) 2006-08-10
GB9719819D0 (en) 1997-11-19
US5736541A (en) 1998-04-07
CN1179160A (zh) 1998-04-15
ATA902196A (de) 2000-01-15
AU706471B2 (en) 1999-06-17
EP0733635B1 (de) 2001-08-16
SI1445259T1 (sl) 2006-10-31
CA2214005A1 (en) 1996-10-03
KR100399688B1 (ko) 2004-02-18
SE9703205D0 (sv) 1997-09-05
AT406771B (de) 2000-08-25
UA44765C2 (uk) 2002-03-15
NZ306110A (en) 1998-09-24
EP1445259B1 (de) 2006-06-28
BR9607790A (pt) 1998-07-07
GB2313835B (en) 1998-09-16
PL322501A1 (en) 1998-02-02
BG62619B1 (bg) 2000-03-31
ZA962342B (en) 1997-09-22
EE9700232A (et) 1998-04-15
YU49478B (sh) 2006-05-25
DE19681286T1 (de) 1998-04-02
IS1896B (is) 2003-10-20
EP0733635A1 (de) 1996-09-25
OA10510A (en) 2002-04-24
AP828A (en) 2000-04-28
EG23659A (en) 2007-03-26
AP9701065A0 (en) 1997-10-31
AR010448A1 (es) 2000-06-28
NO974365D0 (no) 1997-09-22
ES2159346T3 (es) 2001-10-01
CZ300097A3 (en) 1997-12-17

Similar Documents

Publication Publication Date Title
ATE331719T1 (de) Verwendung von kristallformen von 2- methylthienobenzodiazepinen
DE69634998D1 (de) Kontrolle von Kanten
DE69631647D1 (de) Erfassung von möglichem betrügerischen gebrauch von kommunikation
DE69431880D1 (de) Verwendung von (2-imidazolin-2-yl-amino) quinoxalinderivaten
DE69626729D1 (de) Kombination von Datenwerten
DE69628195D1 (de) Verwendung von xyloglucanendotransglycosylase
NL300284I2 (nl) Kristalmodificatie van
ATE172762T1 (de) Verwendung von ethylenaminen bei der lignin- entfernung
DE69531048D1 (de) Verwendung von steroidsulphatase-hemmern
DE59610014D1 (de) Schwingquarzsensor
DE69827393D1 (de) Kosmetische verwendung von bis-resorcinol-triazinderivaten
DE69618264D1 (de) Verbesserungen bei der Herstellung von Kristallsubstraten
DE69612725D1 (de) Kristallhaltevorrichtung
DE59401861D1 (de) Verwendung von ferrocen
DE69605708D1 (de) Reinigung von Pentafluorethan
DE69606449D1 (de) Züchtung von Silizium-Einkristall
DE19681567T1 (de) Flüssigkristallzusammensetzung
DE69515021D1 (de) Ausrichtung von Interferometern
DE59308823D1 (de) Verwendung von Thioalkandionen als Aromastoffe
ATE210605T1 (de) Verwendung von sulfonamiden zur kontrolle von biobewuchs
DE69623886D1 (de) Entfernung von Spleissbändern
DE59501871D1 (de) Monocarbonsäureamide von Polyaminen
DE69508469D1 (de) Oxyde-Granat-Einkristall
DE29622383U1 (de) Verbindungsanordnung von Bauelementen
KR960032349U (ko) 액정표시장치의 백라이트 구조

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1445259

Country of ref document: EP